BioPharmSignal logoBioPharmSignal

Biotech News

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026

Cognition Therapeutics (CGTX)Cognition TherapeuticsEarnings

-- Conference Call and Webcast 8:30 a.m. ET November 5 --

PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced that the Company will host a conference call and webcast on November 5, 2026, at 8:30 a.m. Eastern Time to report its financial results for the third quarter ended September 30, 2026, and provide a business update.

Related news

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

TSHATaysha Gene Therapies2026-11-05 13:00 EST

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

AXSMAxsome2026-10-07 11:00 EST

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

PRAXPraxis Precision Medicines2026-10-27 20:01 EST

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

XERSXeris Pharmaceuticals2026-10-22 12:00 EST

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

ADXNAddex Therapeutics2026-09-24 05:00 EST

Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026

ECORelectroCore2026-10-29 12:00 EST

electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026

TNXPTonix Pharmaceuticals2026-10-26 11:00 EST

Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026

View all latest news

Cognition Therapeutics

Neurodegenerative-Disease Development Cognition Therapeutics develops small-molecule therapies for neurodegenerative disorders. Its work focuses on synaptic dysfunction and toxic protein biology associated with dementia. Zervimesine Zervimesine is an oral sigma-2 receptor modulator being studied in dementia with Lewy bodies and...

Recent company news

CGTXCognition Therapeutics2026-11-02 12:30 EST

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026

CGTXCognition Therapeutics2026-10-22 10:00 EST

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

CGTXCognition Therapeutics2026-09-29 11:30 EST

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

CGTXCognition Therapeutics2026-09-08 11:30 EST

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

CGTXCognition Therapeutics2026-08-06 20:15 EST

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Stock data

Close
0.64 USD
Market cap
120.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States